Physician profile
Maria Orig
NPI 1225054216
$2,147.00
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $304 · 2021: $582 · 2022: $376 · 2024: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $151 · Education: $36.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $150.78 |
| Education | $36.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $343.70 | 2019-2022 | |
| Akebia Therapeutics INC | $308.07 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $296.68 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $194.24 | 2019-2024 | Rayaldee |
| Fresenius USA Marketing, INC. | $166.15 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $156.74 | 2021-2024 | |
| Aurinia Pharma U.S., INC. | $135.25 | 2021-2024 | Lupkynis |
| Amgen INC. | $123.44 | 2020-2024 | Tavneos |
| Vifor Pharma, INC. | $78.27 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $59.99 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.44 | 2022-2024 | Jardiance |
| Travere Therapeutics, INC. | $38.51 | 2019-2022 | |
| Daiichi Sankyo INC. | $35.33 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $27.67 | 2019 | |
| Calliditas Therapeutics US INC. | $23.06 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $21.84 | 2019 | |
| Lilly USA, LLC | $19.86 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $17.49 | 2020 | |
| Shire North American Group INC | $16.18 | 2019 | |
| Sanofi Pasteur INC. | $15.46 | 2020 | |
| Nxstage Medical, INC. | $14.38 | 2019 | |
| Horizon Therapeutics Plc | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Orig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.